Daewoong Co., Ltd. (KRX:003090)
South Korea
· Delayed Price · Currency is KRW 24,300
0.00 (0.00%)
At close: Dec 5, 2025
Daewoong Revenue
Daewoong had revenue of 542.18B KRW in the quarter ending September 30, 2025, with 5.10% growth. This brings the company's revenue in the last twelve months to 2.06T, up 9.35% year-over-year. In the year 2024, Daewoong had annual revenue of 1.94T with 6.79% growth.
Revenue (ttm)
2,055.93B
Revenue Growth
+9.35%
P/S Ratio
0.48
Revenue / Employee
5.42B
Employees
379
Market Cap
993.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,936.92B | 123.08B | 6.79% |
| Dec 31, 2023 | 1,813.84B | 116.50B | 6.86% |
| Dec 31, 2022 | 1,697.34B | 185.96B | 12.30% |
| Dec 31, 2021 | 1,511.37B | 156.04B | 11.51% |
| Dec 31, 2020 | 1,355.34B | -10.34B | -0.76% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5,504.84B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| ABL Bio | 88.44B |
| SK Biopharmaceuticals | 675.41B |
| Yuhan | 2,136.67B |
| LigaChem Biosciences | 159.27B |
| Peptron | 6.19B |